A predictive model for prostate cancer incorporating PSA molecular forms and age.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 02 2020
12 02 2020
Historique:
received:
10
06
2019
accepted:
16
01
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
18
11
2020
Statut:
epublish
Résumé
The diagnostic specificity of prostate specific antigen (PSA) is limited. We aimed to characterize eight anti-PSA monoclonal antibodies (mAbs) to assess the prostate cancer (PCa) diagnostic utility of different PSA molecular forms, total (t) and free (f) PSA and PSA complexed to α
Identifiants
pubmed: 32051423
doi: 10.1038/s41598-020-58836-4
pii: 10.1038/s41598-020-58836-4
pmc: PMC7016114
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2463Références
Jemal, A. et al. Cancer statistics, 2008. CA Cancer J Clin. 58, 71–96 (2008).
pubmed: 18287387
doi: 10.3322/CA.2007.0010
pmcid: 18287387
Pinsky, P. F. et al. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 99, 775–779 (2007).
pubmed: 17223921
doi: 10.1111/j.1464-410X.2007.06708.x
pmcid: 17223921
Filella, X. & Foj, L. Emerging biomarkers in the detection and prognosis of prostate cancer. Clin. Chem. Lab. Med. 53, 963–973 (2015).
pubmed: 25581761
doi: 10.1515/cclm-2014-0988
pmcid: 25581761
Piironen, T. et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin. Chem. 42, 1034–1041 (1996).
pubmed: 8674186
doi: 10.1093/clinchem/42.7.1034
pmcid: 8674186
Stamey, T. A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916 (1987).
pubmed: 2442609
doi: 10.1056/NEJM198710083171501
pmcid: 2442609
Heidenreich, A. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65, 467–479 (2014).
pubmed: 24321502
doi: 10.1016/j.eururo.2013.11.002
pmcid: 24321502
Roach, M. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65, 965–974 (2006).
pubmed: 16798415
doi: 10.1016/j.ijrobp.2006.04.029
pmcid: 16798415
Christensson, A. et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J. Urol. 150, 100–105 (1993).
pubmed: 7685416
doi: 10.1016/S0022-5347(17)35408-3
pmcid: 7685416
Catalona, W. J. et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 151, 1283–1290 (1994).
pubmed: 7512659
doi: 10.1016/S0022-5347(17)35233-3
pmcid: 7512659
Park, J. et al. Low testosterone level is an independent risk factor for high-grade prostate cancer detection at biopsy. B.J.U. Int. 118, 230–235 (2015).
doi: 10.1111/bju.13206
De Luca, S. et al. High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy. B.J.U. Int. 118, 723–730 (2016).
doi: 10.1111/bju.13504
Jablonka, F. et al. Serum crosslinked-N-terminal telopeptide of type I collagen (NTx) has prognostic implications for patients with initial prostate carcinoma (PCa): a pilot study. Clin. Chim. Acta 436, 316–318 (2014).
pubmed: 24992524
doi: 10.1016/j.cca.2014.06.025
Matin, F. et al. A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer. Sci. Rep. 8, 6653, https://doi.org/10.1038/s41598-018-24424-w (2018).
doi: 10.1038/s41598-018-24424-w
pubmed: 29703916
pmcid: 5923293
Shariat, S. F., Karam, J. A., Margulis, V. & Karakiewicz, P. I. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. B.J.U. Int. 101, 675–683 (2008).
doi: 10.1111/j.1464-410X.2007.07283.x
Ferrer-Batallé, M. et al. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection. Int. J. Mol. Sci. 18, https://doi.org/10.3390/ijms18040845 (2017).
pmcid: 5412429
doi: 10.3390/ijms18040845
pubmed: 5412429
Fu, S., Zhang, X., Niu, Y. & Wang, R. T. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia. Asian Pac J Cancer Prev 19, 699–702 (2018).
pubmed: 29580043
pmcid: 5980844
Vickers, A. J. et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. B.M.C. Med. 6, 19 (2008).
Foj, L. et al. Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clin. Chim. Acta 435, 53–58 (2014).
pubmed: 24803095
doi: 10.1016/j.cca.2014.04.025
Vickers, A. et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J. Clin. Oncol. 28, 2493–2498 (2010).
pubmed: 20421547
pmcid: 2881727
doi: 10.1200/JCO.2009.24.1968
Carlsson, S. et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur. Urol. 64, 693–699 (2013).
pubmed: 23683475
pmcid: 3786059
doi: 10.1016/j.eururo.2013.04.040
Boegemann, M. et al. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years. B.J.U. Int. 117, 72–79 (2016).
doi: 10.1111/bju.13139
Filella, X. & Gimenez, N. Evaluation of [−2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin. Chem. Lab. Med. 51, 729–739 (2013).
pubmed: 23154423
Loeb, S., Roehl, K. A., Thaxton, C. S. & Catalona, W. J. Combined prostate-specific antigen density and biopsy features to predict “clinically insignificant” prostate cancer. Urology 72, 143–147 (2008).
pubmed: 18436287
doi: 10.1016/j.urology.2007.11.009
Ström, P., Nordström, T., Grönbergk, H. & Eklund, M. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur. Urol. 74, 204–210 (2018).
pubmed: 29331214
doi: 10.1016/j.eururo.2017.12.028
Pereira-Azevedo, N., Verbeek, J. F. M., Nieboer, D., Bangma, C. H. & Roobol, M. J. Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome. Transl. Androl. Urol. 7, 18–26 (2018).
pubmed: 29594016
pmcid: 5861294
doi: 10.21037/tau.2017.12.21
Liss, M. A., Xu, J., Chen, H. & Kader, A. K. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial. Prostate 75, 1322–1328 (2015).
pubmed: 25982801
doi: 10.1002/pros.23012
Lose, F. et al. Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urol. Oncol. 31, 635–643 (2013).
pubmed: 21741862
doi: 10.1016/j.urolonc.2011.05.011
Chunhua, L. et al. Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer. Transl. Oncol. 11, 628–632 (2018).
pubmed: 29574327
pmcid: 6002384
doi: 10.1016/j.tranon.2018.02.019
España, F. et al. Quantitative immunoassay for complexes of prostate-specific antigen with alpha2-macroglobulin. Clin. Chem. 42, 545–550 (1996).
pubmed: 8605671
doi: 10.1093/clinchem/42.4.545
McCormack, R. T. et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45, 729–744 (1995).
pubmed: 7538236
doi: 10.1016/S0090-4295(99)80076-4
pmcid: 7538236
Zhu, L. et al. PSA forms complexes with α1-antichymotrypsin in prostate. Prostate 73, 219–226 (2013).
pubmed: 22806587
doi: 10.1002/pros.22560
pmcid: 22806587
Zhu, Y. et al. Effect of body mass index on the performance characteristics of PSA-related markers to detect prostate cancer. Sci. Rep. 6, 19034, https://doi.org/10.1038/srep19034 (2016).
doi: 10.1038/srep19034
pubmed: 26754552
pmcid: 4709513
Catalona, W. J. et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J.A.M.A. 274, 1214–1220 (1995).
pubmed: 7563511
doi: 10.1001/jama.1995.03530150038031
pmcid: 7563511
Roddam, A. W. et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur. Urol. 48, 386–399 (2005).
pubmed: 15982797
doi: 10.1016/j.eururo.2005.04.015
pmcid: 15982797
España, F. et al. Free and complexed prostate-specific antigen in the differentiation between benign prostatic hyperplasia and prostate cancer. Studies in serum and plasma samples. J. Urol. 160, 2081–2088 (1998).
pubmed: 9817329
doi: 10.1016/S0022-5347(01)62248-1
pmcid: 9817329
Catalona, W. J. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324, 1156–61 (1991).
pubmed: 1707140
doi: 10.1056/NEJM199104253241702
pmcid: 1707140
Richardsen, E. et al. MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. Sci. Rep. 9, 386, https://doi.org/10.1038/s41598-018-36854-7 (2019).
doi: 10.1038/s41598-018-36854-7
pubmed: 30674952
pmcid: 6344505
Bravaccini, S. et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci. Rep. 8, 4254, https://doi.org/10.1038/s41598-018-22594-1 (2018).
doi: 10.1038/s41598-018-22594-1
pubmed: 29523813
pmcid: 5844862
Bansal, N. et al. Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation. Sci. Rep. 7, 16824, https://doi.org/10.1038/s41598-017-17207-2 (2017).
doi: 10.1038/s41598-017-17207-2
pubmed: 29203798
pmcid: 5715056
Catalona, W. J. et al. A multicenter study of [−2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J. Urol. 185, 1650–1655 (2011).
pubmed: 21419439
pmcid: 3140702
doi: 10.1016/j.juro.2010.12.032
Nordström, T., Akre, O., Aly, M., Grönberg, H. & Eklund, M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 21, 57–63 (2018).
pubmed: 29259293
doi: 10.1038/s41391-017-0024-7
España, F. et al. Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment. Eur. J. Cancer 34, 1375–1380 (1998).
pubmed: 9849420
doi: 10.1016/S0959-8049(98)00078-1
Martínez, M. et al. Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer. Eur. Urol. 38, 85–90 (2000).
pubmed: 10859447
doi: 10.1159/000020257
Vashi, A. R. & Oesterling, J. E. Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer. Mayo Clin. Proc. 72, 337–344 (1997).
pubmed: 9121181
doi: 10.4065/72.4.337
Stephan, C. et al. Multicenter evaluation of [−2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin. Chem. 59, 306–314 (2013).
pubmed: 23213080
doi: 10.1373/clinchem.2012.195784
Na, R. et al. Performance of serum prostate-specific antigen isoform [−2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population. Prostate 74, 1569–1575 (2014).
pubmed: 25176131
doi: 10.1002/pros.22876
Martos, L. et al. α2-macroglobulin is a significant in vivo inhibitor of activated protein C and low APC:α2M levels are associated with venous thromboembolism. Thromb. Haemost. 118, 630–638 (2018).
pubmed: 29448296
pmcid: 6002867
doi: 10.1055/s-0038-1629902
Burnham, K. P. & Anderson, D. R. Multimodel inference: understanding AIC and BIC in Model Selection. Sociol. Methods Res. 33, 261–304 (2004).
doi: 10.1177/0049124104268644
Leening, M. J., Vedder, M. M., Witteman, J. C., Pencina, M. J. & Steyerberg, E. W. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician’s guide. Ann. Intern. Med. 160, 122–131 (2014).
pubmed: 24592497
doi: 10.7326/M13-1522
pmcid: 24592497
Schoonjans, F., Zalata, A., Depuydt, C. E. & Comhaire, F. H. Medcalc: A new computer program for medical statistics. Comput. Methods Programs Biomed. 48, 257–262 (1995).
pubmed: 8925653
doi: 10.1016/0169-2607(95)01703-8